LLY

909.6

+0.73%↑

JNJ

235.91

+0.19%↑

ABBV

204.87

+0.31%↑

NVS

148.15

+1.55%↑

AZN

184.48

+0.61%↑

LLY

909.6

+0.73%↑

JNJ

235.91

+0.19%↑

ABBV

204.87

+0.31%↑

NVS

148.15

+1.55%↑

AZN

184.48

+0.61%↑

LLY

909.6

+0.73%↑

JNJ

235.91

+0.19%↑

ABBV

204.87

+0.31%↑

NVS

148.15

+1.55%↑

AZN

184.48

+0.61%↑

LLY

909.6

+0.73%↑

JNJ

235.91

+0.19%↑

ABBV

204.87

+0.31%↑

NVS

148.15

+1.55%↑

AZN

184.48

+0.61%↑

LLY

909.6

+0.73%↑

JNJ

235.91

+0.19%↑

ABBV

204.87

+0.31%↑

NVS

148.15

+1.55%↑

AZN

184.48

+0.61%↑

Начало・Списък с акции・Lisata Therapeutics

L
Lisata Therapeutics

Отворен

5.01 0.2

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.99

Максимум

5.01

Ключови измерители
By Trading Economics
Приходи	1.3M -3M
Продажби	100K 100K
Марж на печалбата	-2,954
Служители	26

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	19M 39M
Предишно отваряне	4.81
Предишно затваряне	5.01

Lisata Therapeutics Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.03.2026 г., 23:50 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

22.03.2026 г., 23:50 ч. UTC

Пазарно говорене

LG Electronics Set to Stage Strong Earnings Rebound in 1Q -- Market Talk

22.03.2026 г., 23:49 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Lower on Prospects of Liquidity-Driven Sales -- Market Talk

22.03.2026 г., 23:49 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei May Fall as Concerns About Middle East Conflict Persist -- Market Talk

22.03.2026 г., 23:49 ч. UTC

Пазарно говорене

Значими събития в новините

Global Forex and Fixed Income Roundup: Market Talk

22.03.2026 г., 23:41 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Edges Lower as Traders Eye Trump's Deadline to Reopen Strait of Hormuz -- Market Talk

22.03.2026 г., 22:57 ч. UTC

Придобивния, сливания и поглъщания

Perseus Mining: Location of Aurum's Discoveries Present Potential Future Synergies

22.03.2026 г., 22:56 ч. UTC

Придобивния, сливания и поглъщания

Perseus Mining: Aurum Share Acquisition Cost A$23.69 Million

22.03.2026 г., 22:56 ч. UTC

Придобивния, сливания и поглъщания

Perseus Mining: Aurum's Boundiali Gold Project Located to South of Sissingue Gold Mine

22.03.2026 г., 22:55 ч. UTC

Придобивния, сливания и поглъщания

Perseus Mining: Participated in Aurum Resources Equity Raising

22.03.2026 г., 22:54 ч. UTC

Придобивния, сливания и поглъщания

Perseus Mining: Acquires 9.9% Interest in Aurum Resources

22.03.2026 г., 22:22 ч. UTC

Пазарно говорене

Значими събития в новините

After Selloff, Gold Seen Supported by Strait of Hormuz Deadline -- Market Talk

22.03.2026 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Synopsys Has Market Value Over $80 Billion; Major Customers Include Nvidia -- WSJ

22.03.2026 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Activist Elliott Builds Big Stake in Chip-Design Software Maker Synopsys -- WSJ

22.03.2026 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Activist Elliott Investment Management Has Multibillion-Dollar Investment in Synopsys, Sources Say -- WSJ

22.03.2026 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Elliott Plans to Push Synopsys to Make More Money From Its Software and Services, Sources Say -- WSJ

22.03.2026 г., 21:53 ч. UTC

Печалби

Zijin Gold International Plans 59.2 Tons of Gold Production in 2026; up 12.3% on Year >2259.HK

22.03.2026 г., 21:53 ч. UTC

Печалби

Zijin Gold International Rising Gold Prices Supported Results >2259.HK

22.03.2026 г., 21:53 ч. UTC

Печалби

Zijin Gold International 2025 Rev $5.38B Vs. $2.99B >2259.HK

22.03.2026 г., 21:53 ч. UTC

Печалби

Zijin Gold International 2025 Net $1.60B Vs. Net $481.37M >2259.HK

22.03.2026 г., 21:31 ч. UTC

Печалби

China Petroleum & Chemical Plans CNY131.6B-CNY148.6B Capex Spending in 2026>0386.HK

22.03.2026 г., 21:31 ч. UTC

Печалби

China Petroleum & Chemical: Decrease in Sales Volumes of Refined Oil Products Also Hurt Results >0386.HK

22.03.2026 г., 21:31 ч. UTC

Печалби

China Petroleum & Chemical 2025 Results Weighed by Decrease in Prices of Petroleum, Petrochemical Products>0386.HK

22.03.2026 г., 21:31 ч. UTC

Печалби

China Petroleum & Chemical 2025 Rev CNY2.78T Vs. CNY3.07T >0386.HK

22.03.2026 г., 21:31 ч. UTC

Печалби

China Petroleum & Chemical 2025 Net CNY32.48B Vs. Net CNY48.94B >0386.HK

22.03.2026 г., 21:25 ч. UTC

Пазарно говорене

Значими събития в новините

Bonds Decoupling From Oil Amid Longer Conflict Fears -- Market Talk

22.03.2026 г., 21:22 ч. UTC

Придобивния, сливания и поглъщания

St Barbara: Remarks Follow Recent Inquiries About Simberi's Fuel Stocks

22.03.2026 г., 21:21 ч. UTC

Придобивния, сливания и поглъщания

St Barbara: Simberi Currently Uses About 65,000 Liters Per Day For Mining Fleet, Power Generation

22.03.2026 г., 21:21 ч. UTC

Пазарно говорене

Revised Fuel Subsidy Mechanism Positive for Ampol, Viva Energy -- Market Talk

22.03.2026 г., 21:21 ч. UTC

Придобивния, сливания и поглъщания

St Barbara: Has Been Taking Precaution to Increase Diesel Storage For Several Months

Сравнение с други в отрасъла

Ценова промяна

Lisata Therapeutics Прогноза

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Lisata Therapeutics през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Печалба преди облагане с данъци

Продажби

Оперативна печалба

Относно Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.